Detalles de la búsqueda
1.
Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
Ann Surg Oncol
; 28(11): 5960-5971, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821344
2.
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
JAMA Netw Open
; 6(10): e2339584, 2023 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878313
3.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
JAMA Oncol
; 9(4): 490-499, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36602784
4.
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Nat Commun
; 14(1): 7053, 2023 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37923752
5.
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
J Clin Oncol
; 40(36): 4240-4249, 2022 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35867947
6.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
J Clin Oncol
; 40(12): 1323-1334, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35044810
Resultados
1 -
6
de 6
1
Próxima >
>>